CD8A and neoplasm: Caerin 1.1/1.9 inhibited TC-1 tumour growth and modified the functions of tumour infiltrating immune cells, such as T cells, NK cells, and dendritic cells in vivo [23,29], and more activated CD8+ T cells and NK cells were recruited to the tumour sites [23,28,29].